Document |
Document Title |
WO/2012/064417A1 |
The present invention comprises a compound of a compound of Formula 1 wherein Rf is a C2 to C-12 perfluoroalkyl optionally interrupted by one to four moieties each independently selected from the group consisting of -CH2-, -O-, -S-, -S(O...
|
WO/2012/059436A2 |
The invention relates to novel compounds of formula (I), in which R1, R2, R3, R4, R5, Y, Q and G are defined as indicated above, to several methods and intermediate products for the production thereof and use thereof as herbicides and/or...
|
WO/2012/058866A1 |
Provided are a benzamide derivative as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the preparation method and use thereof for preparing a medicine for treating cancer, wherein the group definitions of formula ...
|
WO/2012/058115A2 |
Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in proteomic libraries are of unknown functi...
|
WO/2012/050101A1 |
Provided is a method for producing a urethane compound that makes it possible for a urethanation reaction to advance uniformly and to suppress the generation of byproducts. This method for producing a urethane compound comprises reacting...
|
WO/2012/045967A1 |
The invention relates to a method for preparing an amino acid, or the salts thereof, from 2-aminobutyrolactone (2ABL), wherein said amino acid has formula I, XCH2CH2CHNH2COOH, where X is a nucleophilic ion and, wherein according to the m...
|
WO/2012/046771A1 |
The inventors have intensively studied on compounds that have Aβ42 production inhibitory activity and have found that a compound (I) of the present invention, wherein a carboxylic acid or a tetrazole group is bonded to a cycloalkane moi...
|
WO/2012/038944A1 |
The present invention relates to methyl sulfonamides and N-formamides derivatives of formula (I) and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of...
|
WO/2012/039132A1 |
Disclosed is a method for producing a compound represented by general formula (2) by causing a compound represented by general formula (1) to react with ammonia.
|
WO/2012/035950A1 |
Provided are a novel acrylic acid ester derivative which can be a structural unit of a polymer compound contained in a photoresist composition; the polymer compound which is obtained by polymerization of a starting material containing th...
|
WO/2012/029672A1 |
The present invention relates to amine derivatives each represented by chemical formula (I) (wherein Ar represents a phenyl group or the like; R1 represents a hydrogen atom or the like; R2 represents a C1-6 alkylcarbonyl group or the lik...
|
WO/2012/028676A1 |
The invention relates to new compounds of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
WO/2012/025501A1 |
The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a y-amino-5-biphenyl-a-methylalkanoic acid, or acid ester, backb...
|
WO/2012/025502A1 |
The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, ba...
|
WO/2012/023570A1 |
Provided is an inexpensive, simple, and efficient method for preparing, from a starting material, a nitro compound constituting a diamine precursor compound which is a starting material for producing a polyamic acid and/or polyimide. Com...
|
WO/2012/019428A1 |
Benzohydrol derivatives of formula (I), a preparation method, pharmaceutical compositions and pharmaceutical use thereof are disclosed in the invention. The derivatives can be used as rennin inhibitors to prepare the drugs for the treatm...
|
WO/2012/020724A1 |
A process for preparing aminoadamantyl carbamate derivatives useful as important intermediates for 11βHSD-1 inhibitors is provided. A process for preparing acid addition salts of compounds represented by general formula (II) or solvates...
|
WO/2012/015704A2 |
Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to ...
|
WO/2012/014226A1 |
The present invention discloses novel process for the preparation of (2R)-2-acetamido-N- benzyl-3-methoxypropanamide of Formula I involving novel intermediates of Formula - XIX and Formula - XX.
|
WO/2012/008228A1 |
Disclosed is a method for oxidizing alcohols, wherein it is possible to efficiently oxidize primary alcohols and secondary alcohols and to achieve high reaction efficiency even when air is used as the bulk oxidant. Specifically disclosed...
|
WO/2012/009678A1 |
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.
|
WO/2012/005059A1 |
A method of producing toluene dicarbamate is provided with: a carbamate production step in which toluenediamine, urea and/or an N-unsubstituted carbamic acid ester, and an alcohol are reacted to produce toluene dicarbamate; and a benzoyl...
|
WO/2012/002688A2 |
The invention is directed to a method of treating restless legs syndrome in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.
|
WO/2012/003136A1 |
The application relates to a dental composition comprising a) a compound (A) with the following features: only one backbone unit (U) with 6 to 20 carbon atoms, at least 6 carbon atoms thereof forming an aromatic or an aliphatic cyclic mo...
|
WO/2012/002203A1 |
Disclosed is a production method for obtaining an optically active β-aminocarbonyl compound by a Mannich reaction of an aldimine in which nitrogen is protected and a malonic acid diester, in the presence of optically active BINOL and 1-...
|
WO/2012/000608A2 |
The present invention relates to novel beta-aminoaldehyde derivatives of the formulae (I), (II) and (III), in which the substituents R1 to R5 and A have the meaning given in the description, to a novel process for their preparation, to i...
|
WO/2012/002773A2 |
A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an ac...
|
WO/2012/002538A1 |
Disclosed is a process for preparing anhydride crystals of the compound represented by formula (1) in a high yield and at a high purity, the compound represented by formula (1) being an important intermediate for the preparation of compo...
|
WO/2011/158598A1 |
The disclosed carbamate production method is provided with a urea-producing process, a carbamation process, an ammonia-separating process wherein gas is absorbed in water in the presence of carbonate salt to form water with absorbed gas ...
|
WO/2011/154148A1 |
The invention discloses a number of therapeutic compounds and a method of treating a disorder in mammal.
|
WO/2011/150205A2 |
Methods of producing the compounds of formula (22) and (23) or enantiomers thereof comprising hydroformylation of compounds of the formula (21) or their enantiomers: using Kelliphite as chiral ligand wherein R is -H or an amine-protectin...
|
WO/2011/149071A1 |
Disclosed is a liquid crystal aligning agent which is capable of providing a liquid crystal alignment film that has high mechanical strength and thus exhibits excellent resistance to rubbing. The liquid crystal alignment film is highly r...
|
WO/2011/148297A1 |
The present invention refers to the compounds corresponding to the following general formula (I): (I) wherein: R = C4-C8 alkanoyl; and X = NH-R1 where R1 = H, or an amine protecting group; and/or the pharmaceutically acceptable salts the...
|
WO/2011/141705A1 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic ...
|
WO/2011/135007A1 |
The present invention relates to compounds of formula (I), or pharmaceutically acceptable, stereoisomers, salts or solvates thereof to methods for their synthesis, and use in the treatment of pain.
|
WO/2011/131501A1 |
The invention relates to amino(meth)acrylates obtained from the reaction of amines with a mixture of urethane(meth)acrylates and (meth)acrylated diluent sand their use for making coatings, adhesives, varnishes and inks. The amino(meth)ac...
|
WO/2011/131576A1 |
Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized ...
|
WO/2011/125429A1 |
Disclosed is a method for producing a carbamate compound represented by formula (3), wherein a fluorine-containing carbonate diester compound represented by formula (1) and a non-aromatic diamine compound represented by formula (2) are c...
|
WO/2011/117393A1 |
The present invention refers to the preparation of racemic N-Boc-3-hydroxyadamant-1-yl glycine
|
WO/2011/113884A1 |
The present invention relates to N-carbomethoxy-N-methoxy-(2-chloromethyl)-aniline compounds of the formula I, wherein: n is 0, 1, 2 or 3, each R1 is independently selected from halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4- alkoxy or C1-...
|
WO/2011/112912A1 |
The invention is to pH tuneable amido-gellant that are suitable for use in consumer product compositions.
|
WO/2011/112887A1 |
The invention is to di-amido gellant that are suitable for use in consumer product compositions.
|
WO/2011/110990A1 |
Method of producing a nanoparticle suspension with the steps (i) preparation of an emulsion of a disperse polar phase, where the aqueous phase comprises one or more precursor substances forming the nanoparticles, in a continuous organic ...
|
WO/2011/111677A1 |
Disclosed is a novel bisphosphate compound that can be used with a wide range of reaction substrates and reactions as a catalyst for asymmetric reactions and can achieve an asymmetric reaction with a high yield and high asymmetric yield....
|
WO/2011/102668A2 |
The present invention relates to colchicine derivatives expressed in chemical formula 1, or to pharmaceutically acceptable salts thereof, to a method for preparing said derivatives, and to a pharmaceutical composition comprising said der...
|
WO/2011/101245A1 |
The invention relates to nitrooxyderivatives of Gamma- aminobutyric acid analogs (GABA analogs) for treating neuropathic pain and in particular diabetic neuropathy. The invention also relates to pharmaceutical formulation comprising such...
|
WO/2011/098417A1 |
Substituted cyanobutyrates of the formula I in which the variables are defined according to the description, processes and intermediates for preparing the compounds of the formula I and their N-oxides, their agriculturally suitable salts...
|
WO/2011/095110A1 |
Intermediate compounds which can be used for preparing Lacosamide as well as preparation methods of Lacosamide are provided. The present preparation methods can avoid using expensive CH3I and AgO and can also avoid using Pd-C catalyst.
|
WO/2011/092065A1 |
The present invention relates to nitric oxide releasing derivatives of serotonin norepinephrine reuptake inhibitors and their use for the treatment of pain, having the following general formula (I) or pharmaceutically acceptable salts th...
|
WO/2011/092556A1 |
Herein described is a novel crystalline form of the hydrochloride of the (4- hydroxycarbamoyl-pheny3)-carbamic acid (6-dimethylamino methyl-2- naphtalenyl) ester. In particular, herein described is a polymorph of the hydrochloride of the...
|